DSR-6434

A TLR7 agonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1412.00

1130.00

- +
10mg

￥2400.00

1920.00

- +
25mg

￥5287.00

4230.00

- +
50mg

￥9712.00

7770.00

- +
100mg

￥16562.00

13250.00

- +
200mg

￥0.00

0.00

- +
500mg

￥0.00

0.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

DSR 6434 is an agonist of toll-like receptor 7 (TLR7).¹ It induces reporter gene activity in HEK293 cells expressing human TLR7 (EC₅₀ = 7.9 nM) but not HEK293 cells expressing human TLR8 or TLR9. DSR 6434 (0.64-2,000 nM) induces production of chemokine (C-X-C motif) ligand 10 (CXCL10), IL-12p70, IFN-γ, and TNF-α in splenocytes isolated from Tlr7 wild-type, but not Tlr7^-/-, mice. In vivo, DSR 6434 (0.1 mg/kg) reduces tumor volume and increases survival, as well as potentiates the antitumor effects of ionizing radiation, in a CT26 murine colon cancer model. It also potentiates the antitumor effects of ionizing radiation and decreases the number of metastases in a KHT murine fibrosarcoma model.

1.Adlard, A.L., Dovedi, S.J., Telfer, B.A., et al.A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor modelsInt. J. Cancer135(4)820-829(2014)